Sponsors / VNDA
VNDA

Vanda Pharmaceuticals

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
40Trials in this database
25Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaNCT00254202Vanda PharmaceuticalsPhase 3Completed2006-09-26Actual
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionNCT01218789Vanda PharmaceuticalsPhase 3Unknown2024-12-05Estimated
Relapse Prevention Study in Patients With SchizophreniaNCT01291511Vanda PharmaceuticalsPhase 3Completed2014-03Actual
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisNCT02004041Vanda PharmaceuticalsPhase 2Completed2015-02-19Actual
Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisNCT02651714Vanda PharmaceuticalsPhase 2Completed2017-08-04Actual
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisNCT02970968Vanda PharmaceuticalsPhase 2Completed2018-11Actual
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaNCT03373201Vanda PharmaceuticalsPhase 3Completed2018-03-05Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)NCT03568331Vanda PharmaceuticalsPhase 3Completed2019-12-27Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisNCT03619902Vanda PharmaceuticalsPhase 2Completed2021-01-20Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar PustulosisNCT03633396Vanda PharmaceuticalsPhase 2Completed2021-04-23Actual
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT03772340Vanda PharmaceuticalsPhase 2Completed2019-06-06Actual
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisNCT04028492Vanda PharmaceuticalsPhase 3Completed2025-02-21Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)NCT04140695Vanda PharmaceuticalsPhase 3Terminated2020-10-14Actual
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT04327661Vanda PharmaceuticalsPhase 3Completed2023-04-01Actual
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesNCT04622345Vanda PharmaceuticalsPhase 2Completed2021-05-22Actual
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882Vanda PharmaceuticalsPhase 3Active not recruiting2026-09Estimated
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisNCT04697056Vanda PharmaceuticalsPhase 2Terminated2021-11-19Actual
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashNCT04697069Vanda PharmaceuticalsPhase 2Terminated2021-12-13Actual
Evaluating the Effects of VQW-765 vs. Placebo in Performance AnxietyNCT04800237Vanda PharmaceuticalsPhase 2Completed2022-08-02Actual
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderNCT04819776Vanda PharmaceuticalsPhase 3Completed2022-09-07Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisNCT04856917Vanda PharmaceuticalsPhase 2Completed2022-02-01Actual
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaNCT04856930Vanda PharmaceuticalsPhase 2Completed2022-07-15Actual
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05352893Vanda PharmaceuticalsPhase 3Completed2023-08-17Actual
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesNCT05361707Vanda PharmaceuticalsPhase 3Unknown2025-07Estimated
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05366855Vanda PharmaceuticalsPhase 3Terminated2024-07-12Actual
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT05903924Vanda PharmaceuticalsPhase 3Completed2024-04-06Actual
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613Vanda PharmaceuticalsPhase 3Active not recruiting2027-09-30Estimated
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT06296966Vanda PharmaceuticalsPhase 2Unknown2024-07Estimated
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantNCT06701396Vanda PharmaceuticalsPhase 3Recruiting2025-06-30Estimated
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseNCT06804603Vanda PharmaceuticalsPhase 2Completed2025-10-06Actual
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044Vanda PharmaceuticalsPhase 3Recruiting2028-03Estimated
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisNCT06836557Vanda PharmaceuticalsPhase 3Recruiting2025-12Estimated
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaNCT06953869Vanda PharmaceuticalsPhase 3Recruiting2027-11Estimated
Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968Vanda PharmaceuticalsPhase 3Recruiting2027-11Estimated
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisNCT07065773Vanda PharmaceuticalsPhase 2Active not recruiting2026-09Estimated
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161Vanda PharmaceuticalsPhase 2Recruiting2026-10Estimated
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT07179055Vanda PharmaceuticalsPhase 2Recruiting2026-09Estimated
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578Vanda PharmaceuticalsPhase 3Active not recruiting2026-12Estimated
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisNCT07362017Vanda PharmaceuticalsPhase 3Recruiting2028-08Estimated
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439Vanda PharmaceuticalsPhase 3Recruiting2026-12-01Estimated

Latest recorded trial changes

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

NCT04028492 · Vanda Pharmaceuticals

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD)

+ Updated value

measure: Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

NCT05352893 · Vanda Pharmaceuticals

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

+ Updated value

measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

NCT05352893 · Vanda Pharmaceuticals

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear)

+ Updated value

measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.